西帕依麦孜彼子胶囊联合盐酸坦索罗辛胶囊治疗BPH的临床观察

发布时间：2018-06-17 11:17

本文选题：良性前列腺增生 + 西帕依麦孜彼子胶囊　；参考：《中华男科学杂志》2015年11期

【摘要】：目的:探讨西帕依麦孜彼子胶囊联合盐酸坦索罗辛胶囊治疗良性前列腺增生(BPH)的有效性及安全性。方法:选取2013年7月至2014年6月在我院诊治为BPH的患者60例,分为对照组和联合用药组各30例。其中对照组年龄(62.03±10.19)岁,病程(3.24±2.18)年;联合用药组年龄(64.77±10.33)岁,病程(4.09±2.63)年,对照组单用盐酸坦索罗辛胶囊0.2 mg,每日1次。联合用药组均口服盐酸坦索罗辛胶囊0.2 mg,每日1次,西帕依麦孜彼子胶囊0.5 g,每日3次,共4周。比较两组治疗前后夜尿次数、最大尿流率(Qmax)、残余尿量、国际前列腺症状(IPSS)评分、生存质量量表(QOL)评分等,并记录不良反应发生。结果:治疗前,对照组夜尿次数(3.60±1.81)次、Qmax(10.40±3.53)ml/min、IPSS(22.47±8.58)分、QOL(4.43±1.50)分,联合用药组夜尿次数(3.43±1.61)次、Qmax(10.14±3.43)ml/min、IPSS(21.93±8.79)分、QOL(4.73±1.31)分。治疗4周后,对照组夜尿次数(2.27±1.60)次、Qmax(14.36±3.03)ml/min、IPSS(17.20±8.43)分、QOL(2.93±1.68)分,联合用药组夜尿次数(1.30±1.18)次、Qmax(13.85±3.15)ml/min、IPSS(13.00±1.53)分、QOL(2.57±1.61)分。两组在治疗后其夜尿次数、Qmax、IPSS、QOL均优于治疗前(P均0.05),而治疗前后联合用药组改善情况:夜尿次数[-(2.13±1.11)]次、IPSS[-(8.93±6.01)]分、QOL[-(2.17±1.12)分]优于对照组:夜尿次数[-(1.73±1.07)]次、IPSS[-(4.80±3.87)分]、QOL[-(1.50±1.01)分](P0.05),而Qmax:对照组(3.95±2.53)ml/min,联合用药组(3.72±2.28)ml/min及残余尿量:对照组[-(26.43±30.49)ml],联合用药组[-(34.30±37.43)ml]改善情况无明显差异(P0.05)。对照组中发生不良反应3例(10.00%),联合用药组发生不良反应5例(16.67%),两组中不良反应发生率比较无统计学差异(P0.05)。结论:西帕依麦孜彼子胶囊联合盐酸坦索罗辛胶囊可改善BPH患者症状,提高生活质量。
[Abstract]:Objective: To investigate the efficacy and safety of the capsule combined with tanzosetin hydrochloride capsule for the treatment of benign prostatic hyperplasia (BPH). Methods: 60 patients with BPH in our hospital from July 2013 to June 2014 were selected and divided into 30 cases of the control group and the combination group. The control group was (62.03 + 10.19) years of age and the course of disease was 3.24 + 2.18. The age of the combination group was (64.77 + 10.33) years (64.77 + 10.33) years, the course of disease was (4.09 + 2.63) years, the control group was treated with tanzosorin capsules 0.2 mg, 1 times a day. The combination group was taken orally with tanzosorin capsule 0.2 mg, 1 times a day and 3 times a day, 3 times a day for 4 weeks. The number of nocturnal urine and the maximum urinary flow rate (Qmax) before and after treatment were compared. The residual urine volume, the International Prostatic Symptom (IPSS) score, the quality of life scale (QOL) score and other adverse reactions were recorded. Results: before treatment, the number of nocturnal times in the control group was (3.60 + 1.81), Qmax (10.40 + 3.53) ml/min, IPSS (22.47 + 8.58), QOL (4.43 + 1.50), the number of nocturnal times (3.43 + 1.61), Qmax (10.14 + 3.43) ml/min, IPSS ( 21.93 + 8.79), QOL (4.73 + 1.31). After 4 weeks, the number of nocturnal urine in the control group was (2.27 + 1.60) times, Qmax (14.36 + 3.03) ml/min, IPSS (17.20 + 8.43), QOL (2.93 + 1.68), ml/min, IPSS (IPSS) and QOL (Qmax, IPS) in the group of Qmax (Qmax, IPS). S, QOL were better than before treatment (P 0.05), and the improvement of the combined medication group before and after treatment: the number of nocturnal times [- (2.13 + 1.11)], IPSS[- (8.93 + 6.01)], QOL[- (2.17 + 1.12)) superior to the control group: the number of nocturnal times [- (1.73 + 1.07)], IPSS[- (4.80 + 2.17)], QOL[- (1.50 + 1.01)] (P0.05), and the Qmax: control group (3.95 + 2.17) ml/min, combined medication Group (3.72 + 2.28) ml/min and residual urine volume: control group [- (26.43 + 30.49) ml], combination group (34.30 + 37.43) ml] improvement no significant difference (P0.05). In the control group, 3 cases of adverse reactions (10%), combined group of adverse reactions in 5 cases (16.67%), the incidence of adverse reactions in the two group was not statistically significant (P0.05). Conclusion: Western pas The combination of imazzi and capsule and tamsulosin hydrochloride can improve the symptoms and improve the quality of life of BPH patients.
【作者单位】：广州中医药大学第一附属医院泌尿外科;广州中医药大学第一临床医学院;
【分类号】：R697.3

【参考文献】